Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
House dust mite subcutaneous allergen immunotherapy in Chinese children with allergic rhinitis and/or asthma
ChiCTR2300071876Phase 4Recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of alutard-sq in allergic rhinitis (AR) and allergic asthma (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Serum Der p, Der p 1, and Der p 2 specific IgE at 48 months, Serum and saliva Der p, Der p 1, and Der p 2 specific IgG4 at 48 months and 4 more. Started Jul 2023; status: recruiting.
02
Drugs
alutard-sq
03
Conditions
allergic rhinitis (AR)allergic asthma
Beyond the preview
Go deeper on ChiCTR2300071876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071876.